Biotechnology track competition upgrades to upgrade KPMV's Biotechnology Innovation 50 Enterprise List

Policies and markets of the market make biotechnology especially in China, showing a spectacle of flowers. KPMG recently held the first launching ceremony of the 50 Enterprise Line of KPMG Chinese Biotechnology Innovation 50 in 2022. It shows that in the "Biotechnology Innovation 50 Enterprise List" released on the day, it is displayed from the field of enterprise segments. The highest proportion is ranked third in genetic therapy enterprises; from the top four of Shanghai, Hangzhou, Beijing, and deep in the distribution of cities and regions, the urban cluster agglomeration effect is strong; from the perspective of the establishment time, more than half of the enterprises have been established for more than five years or more. ; From the perspective of financing rounds, more than 50 % of the company's financing rounds are round A or B.

It is understood that the selection and list awards ceremony was sponsored by KPMG China and co -organized by China Merchants Securities Co., Ltd.. The conference also invited outstanding representatives from scientific research, industry, investment, enterprises and other fields. Trends discuss the development of biotechnology innovation enterprises. And jointly witnessed the important moment when the first biotechnology innovation 50 company list of Permaway China was released. The guest representatives of the guests and outstanding enterprises in the field of biotechnology also brought their own corporate case sharing.

Biotechnology innovation ushered in the golden development period

The field of biotechnology is accelerating into another new leading industry after the information industry, which will profoundly change the economic development model and human social lifestyle. The strategic high point of seizing biotechnology and creating the core competitiveness and industrial advantages of the national science and technology has also become an important fulcrum related to China's economic development and strategic deployment in the future.

Wu Guoqiang, vice chairman of KPMG China, said that the biomedical technology industry is rapidly developing from the most developed high -tech industry to the high -tech pillar industry. With the continuous upgrading of population aging, the continuous upgrade of large health consumption, and the gradual release of the new policy of the new medical supervision of the relevant pharmaceutical supervision, the development of the biomedical market in my country is better, and the momentum of high -quality development is becoming increasingly obvious. KPMG has always actively promoted China's innovative ecological development and helping Chinese biotechnology innovation enterprises to grow is one of our important measures. Through our efforts, we link more resources for excellent enterprises. The high -quality and healthy development of the biotechnology innovation industry is our direction.

It can be seen that China is one of the countries with abundant biological resources and a broad consumer market in the world. Relying on strong domestic markets, complete industrial systems, enriching biological resources and significant institutional advantages, the biological economic prospects are broad, and they are ushered in a period of gold. On the other hand, China is entering an aging society, and the demand for medical services will increase day by day. The vast market and surging consumer demand have made Chinese biotechnology targeted, and then participated in global competition.

Innovative technology drives the steady development of biotechnology

From the perspective of the development trend of biotechnology innovation enterprises, the development policies and supervision environment of Chinese biotechnology enterprises are in good condition; the key favorable manifestations of the capital market on promoting the development of biotechnology innovation enterprises are the innovation of the capital market system to help biotechnology innovation enterprises reduce financing thresholds, and the capital market has continued Optimize the sustainable development of biotechnology enterprises; the construction of talent organization capabilities to help the development of biotechnology innovation enterprises.

Yu Zilong, the partner of the KPMG China Life Sciences Industry, said that the "Fourteenth Five -Year Plan" plan will be the top priority of innovation as the new development concept, further strengthening the top planning of China's scientific research field, and Chinese biotechnology innovation enterprises will follow the trend. In order to help achieve the strategic goals of the forefront of science and technology, innovation system, innovation industry, and people's health in the new plan. At present, under the correct guidance of policies and regulations, China's contribution to global research and development of new drugs in R & D pipeline products and first -marketing drugs has become increasingly entered into the world. It has also increased steadily since 2016. In terms of market access after listing, the national medical insurance negotiation cycle is shortened and the access window increases. More and more innovative drugs can be included in the national medical insurance directory through negotiations, and it also provides greater support for innovative drug payment.

It is reported that the entire selection has also attracted the attention of experts and scholars in many related fields. Gao Shaorong, Dean of the School of Life Science and Technology of Tongji University, said that he recognized the vision and original intention of the KPMG's vision and original intention of holding the 50 activities of biotechnology innovation. As a link in China's biotechnology innovation ecosystem, from basic scientific research to clinical transformation, Chinese local innovation enterprises have carried out increasing social responsibility. With the development of China's good innovation environment, such a system of systematic selection in China The mechanism of innovative enterprises is very significant, which can help integrate different aspects of resources in the innovative ecosystem, jointly promote the development of the innovation environment, and improve the innovation capabilities of China's homeland, fill in the clinical unsatisfactory needs and improve the drug Calibration and patient's payment ability are very helpful.

- END -